Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1301-1306

  Cohen, Steven J ^a   Ho, Linus ^a   Ranganathan, Sulabha ^a   Abbruzzese, James L ^a   Alpaugh, R Katherine ^a   Beard, Mary ^a   Lewis, Nancy L ^a   McLaughlin, Susan ^a   Rogatko, André ^a   Perez Ruixo, Juan J ^a   Thistle, Amanda M ^a   Verhaeghe, Tom ^a   Wang, Hao ^a   Weiner, Louis M ^a   Wright, John J ^a   Hudes, Gary R ^a   Meropol, Neal J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIN B; P21 ACTIVATED KINASE; RAS PROTEIN; TIPIFARNIB; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DNAJA1 PROTEIN, HUMAN; FARNESYL TRANS TRANSFERASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 40; QUINOLONE DERIVATIVE; TRANSFERASE;

ANEMIA; ANOREXIA; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME SUBSTRATE; FATIGUE; GENE MUTATION; HUMAN; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WESTERN BLOTTING; ADENOCARCINOMA; ADULT; AGED; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DISEASE PROGRESSION; FARNESYLTRANSTRANSFERASE; FEMALE; HEAT-SHOCK PROTEINS; HSP40 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; QUINOLONES; TREATMENT OUTCOME;

EID: 0038413837     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.040     Document Type: Article

References (28)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220-228, 1996
3. Yeo CJ, Cameron JL, Sohn TA, et al: Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226:248-257, 1997
4. Cohen SJ, Pinover WH, Watson JC, et al: Pancreatic cancer. Curr Treat Options Oncol 1:375-386, 2000
5. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
6. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
7. End DW, Smets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor Rl 15777 in vivo and in vitro. Cancer Res 61:131-137, 2001
8. Grünewald K, Lyons J, Fröhlich A, et al: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041, 1989
9. Sebti SM, Hamilton AD: Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:6584-6593, 2000
10. Hudes GR, Schol J, Baab J, et al: Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 18:156a, 1999 (abstr 601)
11. Miller AB, Hogestraeten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
12. Rogatko A, Litwin S: Phase II studies: Which is worse, false positive or false negative? J Natl Cancer Inst 88:462, 1996
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:547-581, 1958
14. Perez-Ruixo JJ, Cowan KH, Weiner L, et al: Population pharmacokinetics of Zamestra using data from phase I trials. Ninth Meeting of Population Approach Group in Europe, June 6-7, 2002, Paris, France (abstr 21)
15. Van Cutsem E, Karasek P, Oettle H, et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21:130a, 2002 (abstr 517)
16. Macdonald JS, Chansky K, Whitehead R, et al: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 21:138a, 2002 (abstr 548)
17. Adjei AA, Mauer A, Marks R, et al: A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 21:290a, 2002 (abstr 1156)
18. Haas N, Peereboom D, Ranganathan S, et al: Phase II trial of R115777, an inhibitor of farnesyltransferase, in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 21:181a, 2002 (abstr 721)
19. Cunningham D, de Gramont A, Scheithauer W, et al: Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 21:126a, 2002 (abstr 502)
20. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial. Blood 97:3361-3369, 2001
21. Johnston SRD, Hickish T, Houston S, et al: Efficacy and tolerability of two drug regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor in patients with advanced breast cancer. Proc Am Soc Clin Oncol 21:35a, 2002 (abstr 138)
22. Gotlib J, Dugan K, Katamneni U, et al: Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): Preliminary results. Proc Am Soc Clin Oncol 21:4a, 2002 (abstr 14)
23. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
24. Lerner EC, Zhang TT, Knowles DB, et al: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase-I inhibitor in human tumor cell lines. Oncogene 15:1283-1288, 1997
25. Zujewski J, Horak ID, Bol CJ, et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941, 2000
26. Crul M, de Klerk GJ, Swart M, et al: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor RI15777 in advanced cancer. J Clin Oncol 20:2726-2735, 2002
27. Hilgers W, Rosty C, Hahn SA: Molecular pathogenesis of pancreatic cancer. Hematol Oncol Clin North Am. 16:17-35, 2002
28. Cohen SJ, Meropol NJ: Drug development in pancreatic cancer: Finally biology begets therapy. Int J Gastrointest Cancer (in press)